IX BIOPHARMA LTD
(Incorporated in Singapore)
(Company Registration No. 200405621W)

ISSUE AND ALLOTMENT OF SHARES PURSUANT TO EXERCISE OF WARRANTS AND UPDATE ON EXPIRY OF WARRANTS

Unless otherwise defined herein, all capitalised terms used in this announcement shall bear the same meanings ascribed to them in the Notice of Expiry of Warrants issued and announced on 16 June 2026 and the Reminder Expiry of Warrants announced on 6 July 2026.

The Board of Directors (the "**Board**") of iX Biopharma Ltd. (the "**Company**"), and together with its subsidiaries, the "**Group**"), wishes to announce that on 17 July 2026, the Company has allotted and issued 2,774,778 new ordinary shares pursuant to the exercise of Warrants at the exercise price of S$0.06 per warrant share. The number of issued shares of the Company has increased from 1,089,178,341 shares to 1,091,953,119 shares.

The new ordinary shares rank *pari passu* in all respects with the existing shares of the Company and are expected to be listed and quoted on the Singapore Exchange Securities Trading Limited on or around 21 July 2026.

Pursuant to the Warrant Conditions, the **Warrants have expired on Friday, 17 July 2026 at 5.00 p.m.** (the **"Expiry Date"**).

As of the Expiry Date, the Company has received additional valid exercise notices in respect of 1,362,355 Warrants, for which ordinary shares have not been allotted ("**Additional Exercise Notices**"). These Additional Exercise Notices are being processed, and the new ordinary shares arising therefrom will be allotted and issued in due course.

The final cumulative total of 57,138,410 Warrants (including Additional Exercise Notices) which represents 99.35% of all Warrants previously issued, have been exercised.

AS OF THE CLOSE OF BUSINESS AT 5.00 P.M. ON FRIDAY, 17 JULY 2026, ANY SUBSCRIPTION RIGHTS UNDER THE WARRANTS WHICH HAD NOT BEEN EXERCISED HAVE LAPSED AND EVERY WARRANT HAS CEASED TO BE VALID FOR ANY PURPOSE WHATSOEVER.

BY ORDER OF THE BOARD

Eddy Lee Yip Hang
Chairman & CEO
17 July 2026

---

*This announcement has been reviewed by the Company's Sponsor, UOB Kay Hian Private Limited (the "**Sponsor**").*

*This announcement has not been examined or approved by the Singapore Exchange Securities Trading Limited ("**SGX-ST**") and the SGX-ST assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinion made or reports contained in this announcement.*

The contact person for the Sponsor is Mr. Lance Tan, Senior Vice President, at 83 Clemenceau Avenue, #10-01, UE Square, Singapore 239920, telephone: (65) 6590 6881.